Designing HSP90 inhibitor drugs against mutations profiles of cancer patients
International Journal of Frontiers in Biology and Pharmacy Research · 2021
DOI: 10.53294/ijfbpr.2021.1.2.0045 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Frontiers in Biology and Pharmacy Research, 2021. Verfasst von Servet Tunoglu.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Effective drug binding to its specific receptor determines the therapeutic effect. Tumor cells employ Heat Shock Protein 90 (Hsp90) to survive as Hsp90 prevents apoptosis. The protein is the top expressed protein among others. This expression rate further increases in tumor cells and provides a fine target for drug design. However, mutations and copy number variations, single nucleotide polymorphisms of the target gene as well as strong binding of therapeutic agents to the target provide adverse effects.
Aims
This work investigates HSP90 interaction with common inhibitor geldanamycin through key mutations to understand possible effects.
Methods
In silico analysis by YASARA software was employed to reveal interactions between HSP90 WT and its mutant along with geldanamycin.
Results
One key inhibitor-resistant critical residue interaction was monitored for each cytosolic HSP90 isoform. The residues are at critical positions during conformational changes and at the mutated regions of the protein. However, finely designed geldanamycin still tolerates its binding to HSP90.
Conclusion
HSP has no introns and may seem non-mutable, but designing inhibitors by considering structural alterations increases the effectiveness of the drug candidates and limits side effects through in silico experiments.
Zitieren
APA
Tunoglu, S. (2021). Designing HSP90 inhibitor drugs against mutations profiles of cancer patients. International Journal of Frontiers in Biology and Pharmacy Research. https://doi.org/10.53294/ijfbpr.2021.1.2.0045
Vancouver
Tunoglu S. Designing HSP90 inhibitor drugs against mutations profiles of cancer patients. International Journal of Frontiers in Biology and Pharmacy Research. 2021. doi:10.53294/ijfbpr.2021.1.2.0045
BibTeX
@article{Tunoglu2021,
author = {Tunoglu, Servet},
title = {Designing HSP90 inhibitor drugs against mutations profiles of cancer patients},
journal = {International Journal of Frontiers in Biology and Pharmacy Research},
year = {2021},
doi = {10.53294/ijfbpr.2021.1.2.0045}
}
EUVIMED